Sugi Predict

Sugi Predict / Compounds / SCHEMBL10109122

SCHEMBL10109122

SCHEMBL10109122

Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1N(c1nccc(-c2cccnc2)n1)C(C)(C)C

nearest known ligand 0.72

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ABL1 P00519 20/20 0.72
▸ BCR P11274 17/20 0.72
▸ KIT P10721 10/20 0.72
▸ ABL2 P42684 5/20 0.72
▸ PDGFRA P16234 4/20 0.72
▸ LYN P07948 4/20 0.72
▸ PDGFRB P09619 3/20 0.72
▸ SRC P12931 3/20 0.72
▸ SYK P43405 2/20 0.72
▸ EGFR P00533 2/20 0.72
▸ ERBB2 P04626 2/20 0.72
▸ LCK P06239 2/20 0.72
▸ FYN P06241 2/20 0.72
▸ CSF1R P07333 2/20 0.72
▸ FGR P09769 2/20 0.72
▸ BRAF P15056 2/20 0.72
▸ NQO2 P16083 2/20 0.72
▸ EPHA8 P29322 2/20 0.72
▸ FRK P42685 2/20 0.72
▸ BLK P51451 2/20 0.72

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8191704 0.90 ABL1 (0.72) ABL1BCRKITABL2PDGFRA
SCHEMBL23258781 0.90 ABL1 (0.71) ABL1BCRKITABL2PDGFRA
SCHEMBL10075315 0.89 ABL1 (0.70) ABL1BCRKITABL2PDGFRA
SCHEMBL2317952 0.89 ABL1 (0.70) ABL1BCRKITABL2PDGFRA
SCHEMBL25603078 0.85 ABL1 (0.54) ABL1BCRKITABL2PDGFRA
SCHEMBL27810491 0.85 ABL1 (0.78) ABL1BCRKITABL2PDGFRA
Imatinib SCHEMBL29355523 0.84 ABL1 (1.00) ABL1BCRKITABL2PDGFRA
Imatinib SCHEMBL2236091 0.84 ABL1 (1.00) ABL1BCRKITABL2PDGFRA
Imatinib SCHEMBL29351601 0.84 ABL1 (1.00) ABL1BCRKITABL2PDGFRA
Imatinib SCHEMBL3827 0.84 ABL1 (1.00) ABL1BCRKITABL2PDGFRA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230173079-A1 Conjugate Molecules DIVERSE BIOTECH, INC. (US) 2023-06-08 — — US disclosed
US-8101782-B2 Drug hybrid of rivastigmine or physostigmine with tranylcypromine, amoxapine, desipramine, nortriptyline, protriptyline, fluoxetine, fluvoxamine, paroxetine, duloxetine, betahistine, amlodipine, proylhexedrine, rimantadine, desloratadine; Alzheimer's disease; Parkinson's disease, impairment in memory COLUCID PHARMACEUTICALS, INC. (US) 2012-01-24 — — US disclosed
US-8101782-B2 Drug hybrid of rivastigmine or physostigmine with tranylcypromine, amoxapine, desipramine, nortriptyline, protriptyline, fluoxetine, fluvoxamine, paroxetine, duloxetine, betahistine, amlodipine, proylhexedrine, rimantadine, desloratadine; Alzheimer's disease; Parkinson's disease, impairment in memory COLUCID PHARMACEUTICALS, INC. (US) 2012-01-24 — — US disclosed
US-20080261950-A1 Compounds that inhibit cholinesterase COLUCID PHARMACEUTICALS, INC. (US) 2008-10-23 — — US disclosed
US-20080261950-A1 Compounds that inhibit cholinesterase COLUCID PHARMACEUTICALS, INC. (US) 2008-10-23 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080261950-A1 Compounds that inhibit cholinesterase ACHE, BCHE, CHAT ABL1 3946/4885BCR 4463/4885KIT 2169/4885
US-20230173079-A1 Conjugate Molecules CNR2, CNR1, MAG ABL1 255/4885BCR 42/4885KIT 1931/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.